Mesoblast Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEOBF research report →
Companywww.mesoblast.com
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
- CEO
- Silviu Itescu
- IPO
- 2010
- Employees
- 73
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $2.20B
- P/E
- -24.05
- P/S
- 122.19
- P/B
- 3.27
- EV/EBITDA
- -39.28
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -218.67%
- Op Margin
- -572.05%
- Net Margin
- -500.48%
- ROE
- -14.02%
- ROIC
- -12.35%
Growth & Income
- Revenue
- $17.20M · 191.39%
- Net Income
- $-102,142,000 · -16.13%
- EPS
- $-0.09 · 3.59%
- Op Income
- $-62,443,000
- FCF YoY
- -3.88%
Performance & Tape
- 52W High
- $2.59
- 52W Low
- $0.96
- 50D MA
- $1.64
- 200D MA
- $1.59
- Beta
- 0.79
- Avg Volume
- 280
Get TickerSpark's AI analysis on MEOBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MEOBF Coverage
We haven't published any research on MEOBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MEOBF Report →